{"id":"https://openalex.org/W2904033008","doi":"https://doi.org/10.1007/s00213-018-5130-2","title":"Selective adrenergic alpha2C receptor antagonist ameliorates acute phencyclidine-induced schizophrenia-like social interaction deficits in rats","display_name":"Selective adrenergic alpha2C receptor antagonist ameliorates acute phencyclidine-induced schizophrenia-like social interaction deficits in rats","publication_year":2018,"publication_date":"2018-12-10","ids":{"openalex":"https://openalex.org/W2904033008","doi":"https://doi.org/10.1007/s00213-018-5130-2","mag":"2904033008","pmid":"https://pubmed.ncbi.nlm.nih.gov/30535904","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6591184"},"language":"en","primary_location":{"id":"doi:10.1007/s00213-018-5130-2","doi":"https://doi.org/10.1007/s00213-018-5130-2","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00213-018-5130-2","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00213-018-5130-2.pdf","source":{"id":"https://openalex.org/S80334769","display_name":"Psychopharmacology","issn_l":"0033-3158","issn":["0033-3158","1432-2072"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s00213-018-5130-2.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061794365","display_name":"Katja Savolainen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I175532246","display_name":"University of Eastern Finland","ror":"https://ror.org/00cyydd11","country_code":"FI","type":"education","lineage":["https://openalex.org/I175532246"]}],"countries":["FI"],"is_corresponding":true,"raw_author_name":"Katja Savolainen","raw_affiliation_strings":["School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland. katja.savolainen@uef.fi","School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland. katja.savolainen@uef.fi","institution_ids":["https://openalex.org/I175532246"]},{"raw_affiliation_string":"School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland","institution_ids":["https://openalex.org/I175532246"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030989341","display_name":"Jouni A. Ihalainen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I175532246","display_name":"University of Eastern Finland","ror":"https://ror.org/00cyydd11","country_code":"FI","type":"education","lineage":["https://openalex.org/I175532246"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Jouni Ihalainen","raw_affiliation_strings":["School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland","institution_ids":["https://openalex.org/I175532246"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043554503","display_name":"Aaro J. Jalkanen","orcid":"https://orcid.org/0000-0003-1829-4556","observed_orcids":["https://orcid.org/0000-0003-1829-4556"]},"institutions":[{"id":"https://openalex.org/I175532246","display_name":"University of Eastern Finland","ror":"https://ror.org/00cyydd11","country_code":"FI","type":"education","lineage":["https://openalex.org/I175532246"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Aaro J. Jalkanen","raw_affiliation_strings":["School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland","institution_ids":["https://openalex.org/I175532246"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063605821","display_name":"Markus Forsberg","orcid":"https://orcid.org/0000-0002-0335-8142","observed_orcids":["https://orcid.org/0000-0002-0335-8142"]},"institutions":[{"id":"https://openalex.org/I175532246","display_name":"University of Eastern Finland","ror":"https://ror.org/00cyydd11","country_code":"FI","type":"education","lineage":["https://openalex.org/I175532246"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Markus M. Forsberg","raw_affiliation_strings":["School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland","institution_ids":["https://openalex.org/I175532246"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5061794365"],"corresponding_institution_ids":["https://openalex.org/I175532246"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":{"value":4390,"currency":"USD","value_usd":4390},"fwci":0.539,"has_fulltext":true,"cited_by_count":13,"citation_normalized_percentile":{"value":0.67838013,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":96},"biblio":{"volume":"236","issue":"4","first_page":"1245","last_page":"1253"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9800000190734863,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9800000190734863,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.014000000432133675,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/phencyclidine","display_name":"phencyclidine","score":0.7879999876022339},{"id":"https://openalex.org/keywords/negative-symptoms-of-schizophrenia","display_name":"negative symptoms of schizophrenia","score":0.7360000014305115},{"id":"https://openalex.org/keywords/social-interaction-deficits","display_name":"social interaction deficits","score":0.9779999852180481},{"id":"https://openalex.org/keywords/social-withdrawal","display_name":"social withdrawal","score":0.9850000143051147},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.8399999737739563},{"id":"https://openalex.org/keywords/clozapine","display_name":"clozapine","score":0.8029999732971191},{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":1.0},{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":1.0},{"id":"https://openalex.org/keywords/animal-models-of-schizophrenia","display_name":"animal models of schizophrenia","score":0.6320000290870667}],"concepts":[{"id":"https://openalex.org/C2778851735","wikidata":"https://www.wikidata.org/wiki/Q407324","display_name":"Phencyclidine","level":4,"score":0.8471719622612},{"id":"https://openalex.org/C2780864610","wikidata":"https://www.wikidata.org/wiki/Q221361","display_name":"Clozapine","level":3,"score":0.6968233585357666},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.6668528318405151},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.6600199937820435},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5945758819580078},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.5618457198143005},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.5519227981567383},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.5391144752502441},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.4865211844444275},{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.4590770900249481},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.45716392993927},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3530687093734741},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30655765533447266},{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.2590397894382477},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.22285884618759155},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.20073038339614868},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.1985953450202942}],"mesh":[{"descriptor_ui":"D000317","descriptor_name":"Adrenergic alpha-Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000317","descriptor_name":"Adrenergic alpha-Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007398","descriptor_name":"Interpersonal Relations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010622","descriptor_name":"Phencyclidine","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012919","descriptor_name":"Social Behavior","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D017208","descriptor_name":"Rats, Wistar","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018341","descriptor_name":"Receptors, Adrenergic, alpha-2","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D018691","descriptor_name":"Excitatory Amino Acid Antagonists","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1007/s00213-018-5130-2","doi":"https://doi.org/10.1007/s00213-018-5130-2","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00213-018-5130-2","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00213-018-5130-2.pdf","source":{"id":"https://openalex.org/S80334769","display_name":"Psychopharmacology","issn_l":"0033-3158","issn":["0033-3158","1432-2072"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6591184","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6591184","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology (Berl)","raw_type":"Text"},{"id":"pmid:30535904","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30535904","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:erepo.uef.fi:123456789/7197","doi":null,"is_oa":true,"landing_page_url":"https://erepo.uef.fi/handle/123456789/7197","pdf_url":"https://erepo.uef.fi/bitstreams/15e26144-2364-4da3-9aaa-e3ef1a230fe5/download","source":{"id":"https://openalex.org/S4306402418","display_name":"UEF eRepo (University of Eastern Finland)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I175532246","host_organization_name":"University of Eastern Finland","host_organization_lineage":["https://openalex.org/I175532246"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1007/s00213-018-5130-2","doi":"https://doi.org/10.1007/s00213-018-5130-2","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00213-018-5130-2","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00213-018-5130-2.pdf","source":{"id":"https://openalex.org/S80334769","display_name":"Psychopharmacology","issn_l":"0033-3158","issn":["0033-3158","1432-2072"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1768443950","display_name":null,"funder_award_id":"70051/10","funder_id":"https://openalex.org/F4320321855","funder_display_name":"Tekes"}],"funders":[{"id":"https://openalex.org/F4320310055","display_name":"It\u00e4-Suomen Yliopisto","ror":"https://ror.org/00cyydd11"},{"id":"https://openalex.org/F4320320300","display_name":"European Commission","ror":"https://ror.org/00k4n6c32"},{"id":"https://openalex.org/F4320321726","display_name":"Suomen Kulttuurirahasto","ror":"https://ror.org/027xav248"},{"id":"https://openalex.org/F4320321855","display_name":"Tekes","ror":"https://ror.org/02ag8cq23"},{"id":"https://openalex.org/F4320322356","display_name":"Kuopion Yliopistollinen Sairaala","ror":"https://ror.org/00fqdfs68"},{"id":"https://openalex.org/F4320335322","display_name":"European Regional Development Fund","ror":"https://ror.org/00k4n6c32"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2904033008.pdf","grobid_xml":"https://content.openalex.org/works/W2904033008.grobid-xml"},"referenced_works_count":55,"referenced_works":["https://openalex.org/W948085063","https://openalex.org/W1523031842","https://openalex.org/W1529941862","https://openalex.org/W1855737412","https://openalex.org/W1965318376","https://openalex.org/W1981785487","https://openalex.org/W1984746800","https://openalex.org/W1985254321","https://openalex.org/W1986314685","https://openalex.org/W1987248281","https://openalex.org/W1988337840","https://openalex.org/W1991588393","https://openalex.org/W2003935114","https://openalex.org/W2006474959","https://openalex.org/W2007038309","https://openalex.org/W2008763209","https://openalex.org/W2014699148","https://openalex.org/W2025386813","https://openalex.org/W2027285763","https://openalex.org/W2028884770","https://openalex.org/W2028909417","https://openalex.org/W2042971065","https://openalex.org/W2049428499","https://openalex.org/W2053037256","https://openalex.org/W2053701494","https://openalex.org/W2055511334","https://openalex.org/W2057625606","https://openalex.org/W2057994078","https://openalex.org/W2062104945","https://openalex.org/W2063923867","https://openalex.org/W2068337150","https://openalex.org/W2071608242","https://openalex.org/W2084882106","https://openalex.org/W2085157288","https://openalex.org/W2086095198","https://openalex.org/W2090090358","https://openalex.org/W2120431726","https://openalex.org/W2121313171","https://openalex.org/W2138368199","https://openalex.org/W2145468525","https://openalex.org/W2158783892","https://openalex.org/W2169055778","https://openalex.org/W2259704622","https://openalex.org/W2407135957","https://openalex.org/W2411543049","https://openalex.org/W2419446949","https://openalex.org/W2467768286","https://openalex.org/W2468144236","https://openalex.org/W2472844507","https://openalex.org/W2529553305","https://openalex.org/W2560266276","https://openalex.org/W2598033998","https://openalex.org/W2741165379","https://openalex.org/W2761387669","https://openalex.org/W4249571112"],"related_works":["https://openalex.org/W2003935114","https://openalex.org/W2068337150","https://openalex.org/W2728190211","https://openalex.org/W2032193303","https://openalex.org/W2095457266","https://openalex.org/W2182936853","https://openalex.org/W2411543049","https://openalex.org/W2108468488","https://openalex.org/W2529553305","https://openalex.org/W2053701494"],"abstract_inverted_index":{"Social":[0],"withdrawal":[1],"is":[2,25,234],"a":[3,26,102,235],"core":[4],"feature":[5],"of":[6,10,34,66,122,210,241,245],"the":[7,20,32,64,120,202,211,219,223,239,242],"negative":[8,21,243],"symptoms":[9,244],"schizophrenia.":[11,246],"Currently":[12],"available":[13],"pharmacotherapies":[14],"have":[15],"only":[16],"limited":[17],"efficacy":[18],"towards":[19],"symptoms,":[22],"i.e.,":[23],"there":[24],"significant":[27],"unmet":[28],"medical":[29],"need":[30],"in":[31,59,109,179],"treatment":[33,240],"these":[35],"symptoms.":[36],"We":[37],"wanted":[38],"to":[39,62,72,118,217],"confirm":[40,228],"whether":[41],"selective":[42,188],"adrenergic":[43],"\u03b1":[44,68,78,124,136,189,204,230],"2C":[45,69,125,190,231],"receptor":[46,82],"(AR)":[47],"antagonist":[48,71,127,192],"therapy":[49],"could":[50],"ameliorate":[51],"acute":[52,97],"phencyclidine":[53],"(PCP)-induced":[54],"schizophrenia-like":[55],"social":[56,106,166,180,196],"interaction":[57,107,167,181,197],"deficits":[58,108,178,221],"rats,":[60],"and":[61,100,113,130,145,155,161,176],"compare":[63,119],"effects":[65,121],"an":[67,77,123,135],"AR":[70,126,191,232],"another":[73],"putative":[74],"therapeutic":[75],"alternative,":[76],"7":[79,137,205],"nicotinic":[80],"acetylcholine":[81],"(nAChR)":[83],"partial":[84,139,203],"agonist,":[85],"as":[86],"well":[87],"against":[88],"three":[89,146,212],"commonly":[90],"used":[91,96,115],"atypical":[92,147,213],"antipsychotics.":[93],"Here,":[94],"we":[95],"PCP":[98,170],"administration":[99],"modified":[101],"protocol":[103],"for":[104,238],"testing":[105],"male":[110],"Wistar":[111],"rats":[112],"then":[114],"this":[116],"model":[117],"(ORM-13070":[128],"0.3":[129,142],"1.0":[131],"mg/kg":[132,143,151,157,163,172],"s.c.)":[133,144,164,173],"with":[134],"nAChR":[138,206],"agonist":[140,207],"(EVP-6124":[141],"antipsychotics":[148,214],"(clozapine":[149],"2.5":[150],"i.p.,":[152],"risperidone":[153],"0.04":[154],"0.08":[156],"s.c.,":[158],"olanzapine":[159],"0.125":[160],"0.5":[162],"on":[165],"behavior.":[168],"Acute":[169],"(1.5":[171],"produced":[174],"robust":[175],"reproducible":[177],"behavior":[182],"without":[183],"affecting":[184],"locomotor":[185],"activity.":[186],"The":[187],"significantly":[193],"ameliorated":[194],"PCP-induced":[195],"deficits.":[198],"In":[199],"contrast,":[200],"neither":[201],"nor":[208],"any":[209],"were":[215],"able":[216],"reverse":[218],"behavioral":[220],"at":[222],"selected":[224],"doses.":[225],"Our":[226],"findings":[227],"that":[229],"antagonism":[233],"potential":[236],"mechanism":[237]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2018-12-22T00:00:00"}